蛋白激酶2抑制剂克服表皮生长因子受体-酪氨酸激酶抑制剂耐药的有效机制
表皮生长因子受体-酪氨酸激酶抑制剂（EGFR-TKIs）在肺癌治疗中发挥着重要作用，同时EGFR-TKIs的耐药也成为了肺癌治疗领域的一大难题。近年来的研究表明，蛋白激酶2（CK2）的表达及激活失衡在肿瘤的发生、发展中发挥重要作用，且CK2抑制剂已被多次证实具有抗肿瘤疗效。文章中阐述了EGFR-TKIs的抗肿瘤作用机制以及可能的耐药机制，结合CK2的作用机制及目前CK2抑制剂在抗肿瘤治疗领域的表现，发现了EGFR与CK2下游信号通路存在交联，抑制CK2将有可能克服EGFR-TKI耐药现象。...
Saved in:
| Published in | 中华肿瘤杂志 Vol. 38; no. 5; pp. 321 - 324 |
|---|---|
| Main Author | |
| Format | Journal Article |
| Language | Chinese |
| Published |
华中科技大学同济医学院附属协和医院肿瘤中心, 武汉,430023%华中科技大学同济医学院药剂科, 武汉,430023
2016
|
| Subjects | |
| Online Access | Get full text |
| ISSN | 0253-3766 |
| DOI | 10.3760/cma.j.issn.0253-3766.2016.05.001 |
Cover
| Abstract | 表皮生长因子受体-酪氨酸激酶抑制剂（EGFR-TKIs）在肺癌治疗中发挥着重要作用，同时EGFR-TKIs的耐药也成为了肺癌治疗领域的一大难题。近年来的研究表明，蛋白激酶2（CK2）的表达及激活失衡在肿瘤的发生、发展中发挥重要作用，且CK2抑制剂已被多次证实具有抗肿瘤疗效。文章中阐述了EGFR-TKIs的抗肿瘤作用机制以及可能的耐药机制，结合CK2的作用机制及目前CK2抑制剂在抗肿瘤治疗领域的表现，发现了EGFR与CK2下游信号通路存在交联，抑制CK2将有可能克服EGFR-TKI耐药现象。 |
|---|---|
| AbstractList | 表皮生长因子受体?酪氨酸激酶抑制剂（ EGFR?TKIs ）在肺癌治疗中发挥着重要作用，同时EGFR?TKIs的耐药也成为了肺癌治疗领域的一大难题。近年来的研究表明，蛋白激酶2（ CK2）的表达及激活失衡在肿瘤的发生、发展中发挥重要作用，且CK2抑制剂已被多次证实具有抗肿瘤疗效。文章中阐述了EGFR?TKIs的抗肿瘤作用机制以及可能的耐药机制，结合CK2的作用机制及目前CK2抑制剂在抗肿瘤治疗领域的表现，发现了EGFR与CK2下游信号通路存在交联，抑制CK2将有可能克服EGFR?TKI耐药现象。 表皮生长因子受体-酪氨酸激酶抑制剂（EGFR-TKIs）在肺癌治疗中发挥着重要作用，同时EGFR-TKIs的耐药也成为了肺癌治疗领域的一大难题。近年来的研究表明，蛋白激酶2（CK2）的表达及激活失衡在肿瘤的发生、发展中发挥重要作用，且CK2抑制剂已被多次证实具有抗肿瘤疗效。文章中阐述了EGFR-TKIs的抗肿瘤作用机制以及可能的耐药机制，结合CK2的作用机制及目前CK2抑制剂在抗肿瘤治疗领域的表现，发现了EGFR与CK2下游信号通路存在交联，抑制CK2将有可能克服EGFR-TKI耐药现象。 |
| Abstract_FL | Nowadays, EGFR?TKIs are important treatment strategy in lung cancer, but the resistance to EGFR?TKIs remains an unsolved issue preventing the patients from further benefits. Recent studies have shown that casein kinase ( CK2) plays an important role in carcinogenesis and development of cancer. CK2 inhibitor has also demonstrated anti?tumor effects. Here we reviewed the mechanism of EGFR?TKIs and the potential reasons of resistance. Interestingly, there is a crosstalk between CK2 and EGFR downstream signaling pathways, therefore, it may be possible that CK2 inhibitor can overcome the EGFR?TKIs resistance. |
| Author | 周瑜 张盛 李珂 董晓荣 刘莉 伍钢 孟睿 |
| AuthorAffiliation | 华中科技大学同济医学院附属协和医院肿瘤中心,武汉430023 华中科技大学同济医学院附属协和医院药剂科,武汉430023 |
| AuthorAffiliation_xml | – name: 华中科技大学同济医学院附属协和医院肿瘤中心, 武汉,430023%华中科技大学同济医学院药剂科, 武汉,430023 |
| Author_FL | Dong Xiaorong Zhou Yu Li Ke Meng Rui Liu Li Wu Gang Zhang Sheng |
| Author_FL_xml | – sequence: 1 fullname: Zhou Yu – sequence: 2 fullname: Zhang Sheng – sequence: 3 fullname: Li Ke – sequence: 4 fullname: Dong Xiaorong – sequence: 5 fullname: Liu Li – sequence: 6 fullname: Wu Gang – sequence: 7 fullname: Meng Rui |
| Author_xml | – sequence: 1 fullname: 周瑜 张盛 李珂 董晓荣 刘莉 伍钢 孟睿 |
| BookMark | eNo9kEtLAlEYhs_CIDP_RBC0mek758wcp2VINxDauJczM2d0RMdyiMiVRIImklESqVDtJOiykgjEP9Pc_kUThqsPHp73_eBdQwmn5giEtjDINMNg26hyuSzbruvIQFQqxZDJBDCTQZUBcAIll3wVpV3X1kHFlGkUsyTSw1E3eJz582bUmhL_-tZrT73Opdfq-uNe-DIJhu_B_VM0mHujZ--t7908_MzupKj16n9OotbXIreMhc1-2PsIhlf-uOMP2v74O-braMXiFVek_28K5ff38tlDKXd8cJTdzUmGmsGSpmCLkR1FZ9wQxOSgGUIoJjF3mAAddI4BA3DF4GaGEkGxCcLizNA1ZjFdMWgKbS5qz7ljcadYKNfO6k78sNAoNSp_g4AazxF7GwvPKNWc4qkdmyd1u8rrFwXGNE0FohH6C_bJiQs |
| ContentType | Journal Article |
| Copyright | Copyright © Wanfang Data Co. Ltd. All Rights Reserved. |
| Copyright_xml | – notice: Copyright © Wanfang Data Co. Ltd. All Rights Reserved. |
| DBID | 2RA 92L CQIGP W91 ~WA 2B. 4A8 92I 93N PSX TCJ |
| DOI | 10.3760/cma.j.issn.0253-3766.2016.05.001 |
| DatabaseName | 维普_期刊 中文科技期刊数据库-CALIS站点 维普中文期刊数据库 维普中文医药期刊数据库 中文科技期刊数据库- 镜像站点 Wanfang Data Journals - Hong Kong WANFANG Data Centre Wanfang Data Journals 万方数据期刊 - 香港版 China Online Journals (COJ) China Online Journals (COJ) |
| DatabaseTitleList | |
| DeliveryMethod | fulltext_linktorsrc |
| DocumentTitleAlternate | The underlying mechanisms of overcoming EGFR-TKIs resistance by casein kinase 2 inhibitor |
| DocumentTitle_FL | The underlying mechanisms of overcoming EGFR-TKIs resistance by casein kinase 2 inhibitor |
| EndPage | 324 |
| ExternalDocumentID | zhzl201605001 668850282 |
| GrantInformation_xml | – fundername: 国家自然科学基金青年基金; 武汉市科技局应用基础研究资助项目; 湖北省自然科学基金 funderid: (81101690); (2014060101010034); (2014cfb403) |
| GroupedDBID | --- -05 123 2B. 2C~ 2RA 92F 92I 92L ABDBF ACGFS ALMA_UNASSIGNED_HOLDINGS CCEZO CIEJG CQIGP CW9 EOJEC OBODZ TCJ TGQ U1G U5O W91 ~WA 4A8 93N ABJNI ACUHS PSX |
| ID | FETCH-LOGICAL-c571-841f6294b6ace2da08cee4d2d96e0b0ba10100a4cad732e31d0efa6cb86f6b4c3 |
| ISSN | 0253-3766 |
| IngestDate | Thu May 29 04:00:01 EDT 2025 Wed Feb 14 10:19:26 EST 2024 |
| IsPeerReviewed | false |
| IsScholarly | true |
| Issue | 5 |
| Keywords | Drug resistance,neoplasm 蛋白激酶2 表皮生长因子受体-酪氨酸激酶抑制剂 抗药性,肿瘤 Protein kinase 2 肺肿瘤 Subject words] Lung neoplasms Epidermal growth factor receptor-tyrosine kinase inhibitors |
| Language | Chinese |
| LinkModel | OpenURL |
| MergedId | FETCHMERGED-LOGICAL-c571-841f6294b6ace2da08cee4d2d96e0b0ba10100a4cad732e31d0efa6cb86f6b4c3 |
| Notes | Nowadays, EGFR-TKIs are important treatment strategy in lung cancer, but the resistance to EGFR-TKIs remains an unsolved issue preventing the patients from further benefits. Recent studies have shown that casein kinase （CK2） plays an important role in carcinogenesis and development of cancer. CK2 inhibitor has also demonstrated anti-tumor effects. Here we reviewed the mechanism of EGFR- TKIs and the potential reasons of resistance. Interestingly, there is a crosstalk between CK2 and EGFR downstream signaling pathways, therefore, it may be possible that CK2 inhibitor can overcome the EGFR- TKIs resistance. 11-2152/R Zhou Yu, Zhang Sheng, Li Ke, Dong Xiaorong, Liu Li, Wu Gang, Meng Rui（ Cancer Center, Union Hospital, Tongfi Medical College, Huazhong University of Science and Technology, Wuhan 430023, China, Department of Pharmacy, Union Hospital, Tongii Medical College, Huazhong University of Science and Technology, Wuhan 430023, China） Lung neoplasms; Epidermal growth factor receptor-tyrosine kinase inhibitors;Pr |
| PageCount | 4 |
| ParticipantIDs | wanfang_journals_zhzl201605001 chongqing_primary_668850282 |
| PublicationCentury | 2000 |
| PublicationDate | 2016 |
| PublicationDateYYYYMMDD | 2016-01-01 |
| PublicationDate_xml | – year: 2016 text: 2016 |
| PublicationDecade | 2010 |
| PublicationTitle | 中华肿瘤杂志 |
| PublicationTitleAlternate | Chinese Journal of Oncology |
| PublicationTitle_FL | Chinese Journal of Oncology |
| PublicationYear | 2016 |
| Publisher | 华中科技大学同济医学院附属协和医院肿瘤中心, 武汉,430023%华中科技大学同济医学院药剂科, 武汉,430023 |
| Publisher_xml | – name: 华中科技大学同济医学院附属协和医院肿瘤中心, 武汉,430023%华中科技大学同济医学院药剂科, 武汉,430023 |
| SSID | ssib051368316 ssib007279245 ssib000995398 ssj0042033 ssib017477325 ssib006576341 ssib001103529 ssib058574917 |
| Score | 2.1065233 |
| Snippet | 表皮生长因子受体-酪氨酸激酶抑制剂（EGFR-TKIs）在肺癌治疗中发挥着重要作用，同时EGFR-TKIs的耐药也成为了肺癌治疗领域的一大难题。近年来的研究表明，蛋白激酶2（CK2）... 表皮生长因子受体?酪氨酸激酶抑制剂（ EGFR?TKIs ）在肺癌治疗中发挥着重要作用，同时EGFR?TKIs的耐药也成为了肺癌治疗领域的一大难题。近年来的研究表明，蛋白激酶2（... |
| SourceID | wanfang chongqing |
| SourceType | Aggregation Database Publisher |
| StartPage | 321 |
| SubjectTerms | 抗药性 肺肿瘤 肿瘤 蛋白激酶2 表皮生长因子受体-酪氨酸激酶抑制剂 |
| Title | 蛋白激酶2抑制剂克服表皮生长因子受体-酪氨酸激酶抑制剂耐药的有效机制 |
| URI | http://lib.cqvip.com/qk/93685X/201605/668850282.html https://d.wanfangdata.com.cn/periodical/zhzl201605001 |
| Volume | 38 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| journalDatabaseRights | – providerCode: PRVEBS databaseName: EBSCOhost Academic Search Ultimate issn: 0253-3766 databaseCode: ABDBF dateStart: 20150223 customDbUrl: https://search.ebscohost.com/login.aspx?authtype=ip,shib&custid=s3936755&profile=ehost&defaultdb=asn isFulltext: true dateEnd: 99991231 titleUrlDefault: https://search.ebscohost.com/direct.asp?db=asn omitProxy: true ssIdentifier: ssj0042033 providerName: EBSCOhost |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwvV1LaxRBEB7CBsSLKCrGaMjBBi8TZ6ene7qPPbuzBEFPEXJb5pkguvGRXPYUxIXEEIxoEJOAeguCj1MQIeSHeHVf_8Lq7tnZiZFEPXgZavtRXfVVz3RV09VrGNfclIRhGkamkzoBPFhgcjdOTQ5S08gicZLI5ORbt-n0HefmLJkdKX0vnFpaWgynouZv80r-xapQBnaVWbJ_YdmcKRQADfaFJ1gYnn9kY-QzxD3EPOS7iHPkVZFPkVeTxxd8jhhBHrVlEROIl5FPEGNQpAiothVBVH-KeAWxquQoykgwxVEg4SvCQbwmOXIiuUMvGFVYkhBVxBXBaoi7yHekEByb2fhCKIksxVFLxI7KeKyITB_GUEQViVomGXMGQnNFqI66xBM5n6LvrYRjUmJZW0XMVzxtpRLwhCrNs5pB40mVBjNSaZ0jU4ZxijVeReHhSmC4N6zR3BSIABCzhzVMccOqCQCLB_rh4j6MThBV70xB6FwNFwkli4aPaYM4slBbRigcATtWUaAT1Z3In55XaMOlCMLOCIksaAQq-oNBtc1txSfvnvc6CmIBaGlpLF9kKUE2HpXcwW52xcGWutSD_Bf18hmUT67BEMfLV1gtbYLlakmLSztmhU8YKazTWKflZy4f1mn8v3oT8rwYfAKi-8HUXTXIVD6IPBNK1ZW_2Vbc4Tvbm_PNe7KFRSyZWzpqy83CkjEqvKpXK0Q3nBRv3wRPHMKhYXRBCSz-hWjFlZd9Dg8BkDKmDA-jOwj8XUftvmhH1LEtrA7YDIQ-ZVzPtLpxkk7yppn5hcbcQ_CfVTpjIw0acwXPe-ascSYLmSeF_v6dM0aa8-eNsLe91n2z3zlY7rf27M6zF-2Vvfbqk3ZrrbOz3nu_29361H31tr950N5-1_640X7--sf-S7Pf-tD5sttvfdX98m695Y3e-ufu1tPOzmpnc6Wz8w3KLxgzNX-mMm1m_xdjRsQtm8wpp9TmTkiDKLHjwGIQADixHXOaWKEVBuB9WFbgREHsYjvB5dhK0oBGIaMpDZ0IXzRKjYVGcsmYTHkMXBiPXYgwMdTGACysYRyWL15OgjFjPIen_kBfC1SnlDEit7DGjIkMsHq2WDyuH5oRl09qMG6clrTe6r1ilBYfLSVXIfhZDCeySfQTfI0GfA |
| linkProvider | EBSCOhost |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=%E8%9B%8B%E7%99%BD%E6%BF%80%E9%85%B62%E6%8A%91%E5%88%B6%E5%89%82%E5%85%8B%E6%9C%8D%E8%A1%A8%E7%9A%AE%E7%94%9F%E9%95%BF%E5%9B%A0%E5%AD%90%E5%8F%97%E4%BD%93-%E9%85%AA%E6%B0%A8%E9%85%B8%E6%BF%80%E9%85%B6%E6%8A%91%E5%88%B6%E5%89%82%E8%80%90%E8%8D%AF%E7%9A%84%E6%9C%89%E6%95%88%E6%9C%BA%E5%88%B6&rft.jtitle=%E4%B8%AD%E5%8D%8E%E8%82%BF%E7%98%A4%E6%9D%82%E5%BF%97&rft.au=%E5%91%A8%E7%91%9C&rft.au=%E5%BC%A0%E7%9B%9B&rft.au=%E6%9D%8E%E7%8F%82&rft.au=%E8%91%A3%E6%99%93%E8%8D%A3&rft.date=2016&rft.pub=%E5%8D%8E%E4%B8%AD%E7%A7%91%E6%8A%80%E5%A4%A7%E5%AD%A6%E5%90%8C%E6%B5%8E%E5%8C%BB%E5%AD%A6%E9%99%A2%E9%99%84%E5%B1%9E%E5%8D%8F%E5%92%8C%E5%8C%BB%E9%99%A2%E8%82%BF%E7%98%A4%E4%B8%AD%E5%BF%83%2C+%E6%AD%A6%E6%B1%89%2C430023%25%E5%8D%8E%E4%B8%AD%E7%A7%91%E6%8A%80%E5%A4%A7%E5%AD%A6%E5%90%8C%E6%B5%8E%E5%8C%BB%E5%AD%A6%E9%99%A2%E8%8D%AF%E5%89%82%E7%A7%91%2C+%E6%AD%A6%E6%B1%89%2C430023&rft.issn=0253-3766&rft.volume=38&rft.issue=5&rft.spage=321&rft.epage=324&rft_id=info:doi/10.3760%2Fcma.j.issn.0253-3766.2016.05.001&rft.externalDocID=zhzl201605001 |
| thumbnail_s | http://utb.summon.serialssolutions.com/2.0.0/image/custom?url=http%3A%2F%2Fimage.cqvip.com%2Fvip1000%2Fqk%2F93685X%2F93685X.jpg http://utb.summon.serialssolutions.com/2.0.0/image/custom?url=http%3A%2F%2Fwww.wanfangdata.com.cn%2Fimages%2FPeriodicalImages%2Fzhzl%2Fzhzl.jpg |